we anticipate that the Parsortix system will be a crucial component for the development of drugs targeting the metastatic cascade..... Alongside our ongoing collaboration with ETH Zurich, we look forward to working with PAGE Therapeutics to support their development drugs targeting metastatic spread."Fantastic newsWell done Angle Team. Another breakthrough research paper....momentum building |
I do talk 'drivel' - post #22949 |
(Sharecast News) - Liquid biopsy specialist Angle announced on Friday that its Parsortix system played a pivotal role in groundbreaking breast cancer research published in Nature Medicine by a team led by professor Nicola Aceto at ETH Zurich. |
Bermuda - I see that Page Therapeutics has Meret Gaugler on the board. She was appointed as 'Partner-at-Large in the Growth Investments team of Novo Holdings' in the middle of last year, so if he produces any decent human results he won't be short of friends with deep pockets to help. As you say - worth keeping an eye on. |
there may very well be a pharmaceutical co more advanced in the clinical trials arena that may implement Angle technology and with positive results then Fastrack Designation will be achieved to eradicate cancer. Well done the angle team.....🐭 |
Tight lines...love it.Ps I'm a buyer (watch Game stop film) |
A little competition for your services is never a bad thing. There are no 'barriers to entry' as such but the patents and of course FDA approval is a big lure.
Tight lines! |
An online article published only this morning in the top journal on the planet illustrating the fundamental part Parsortix has played in facilitating a whole new approach to cancer treatment. PR gold & Newland is quite rightly proud of his team. |
"“Parsortix system is the ONLY liquid Biopsy solution with FDA product clearance for harvesting intact cancer cells from patient blood for analysis.”
Is that statement actually true ? FDA approval for Parsortix seems to be an anomaly rather than a recomendation.
There are various alternative systems. |
A cracking RNS. Will be fascinating to see how Nicola Aceto takes this forward:-
'In the next step, the researchers want to develop new molecules based on digoxin that are even better at dissolving the CTC clusters. The ETH spin-off, Page Therapeutics is already working on this solution.
Aceto also wants to expand his research to other types of cancer that spread, such as prostate, colorectal or pancreatic cancer, as well as melanoma. Initial experiments in his laboratory have already begun.' |
Nice turn around this morn, onwards and upwards, GLA |
Looks to me like they are trying to stimulate buying to get an equity raise done. |
News due on many fronts that cound be transformational.
$100 Billion Liquid Biopsy Market in the US alone.
“Parsortix system is the ONLY liquid Biopsy solution with FDA product clearance for harvesting intact cancer cells from patient blood for analysis”
Now have a re-think on value here. |
ANGLE PLC says Nature Medicine journal highlights Parsortix's role in cancer breakthrough. |
hxxps://pagetherapeutics.com/ |
Musician Mike Peters (Lead Singer of The Alarm) was diagnosed with a rapidly progressive blood cancer requiring medical treatment and was undergoing treatment at Christies hospital in Manchester. |
With the vast majority of cancer deaths caused by the metastatic spread of the primary cancer to other organs, such as bones, liver, lungs and brain, a targeted treatment to disassociate CTC clusters could enable CTCs to be targeted by the body's own immune system and increase the effectiveness of existing cytotoxic treatments. This could result in a profound improvement in treatment success and patient survival across all solid tumours. |
RNS Reach this morning. Its well worth a read. |
Demand steadily growing. The greater the participation the better.
Good stuff.
more to come...
'picks n' shovels' |
Big clue in that sentence is potential . It's had potential for many years now and failed to deliver on it hence the number of doubters now |
Lionheart ,I don't think your alone unfortunately decisions were made years ago that meant this was the path chosen and unfortunately the fund raises and lack of progress have seen the share price fall . Looks like more years of waiting looking at the figures too hence the selling . People are fed up and time is running out fast . The next fund raise in a few months time might spell the end of any chance of recovering losses here and why I am sat on the sidelines watching it play out . So far it's going as I predicted months ago . Everyone waiting to see if the follow on deals materialise and what new deals get announced if any . Revenues heading up but at a snails pace isn't what is needed |
Maybe AGL Board should invite investment from Flagship ? |
Imagine them at 20p. |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
